αvβ3 Integrin and tumour blood vessels - learning from the past to shape the future

被引：85

作者：

Demircioglu, Fevzi ^{[1
]}

Hodivala-Dilke, Kairbaan ^{[1
]}

机构：

[1] Queen Mary Univ London, John Vane Sci Ctr, Barts Canc Inst, Ctr Tumour Biol, Charterhouse Sq, London EC1 M 6BQ, England

来源：

CURRENT OPINION IN CELL BIOLOGY | 2016年 / 42卷

基金：

英国医学研究理事会;

关键词：

NEWLY-DIAGNOSED GLIOBLASTOMA; RANDOMIZED PHASE-II; STANDARD TREATMENT; OPEN-LABEL; ANGIOGENESIS; CILENGITIDE; GROWTH; ALPHA(V)BETA(3); CANCER; EXPRESSION;

D O I：

10.1016/j.ceb.2016.07.008

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Angiogenesis, the formation of new blood vessels from preexisting ones, is thought to enhance tumour growth and these blood vessels can act as conduits of tumour cell metastasis. Integrins, the family of cell surface extracellular matrix receptors, can promote endothelial cell migration and survival, both essential features of angiogenesis, and were thus considered good targets for anti-angiogenic therapy. This sparked the development of agents to block integrin function as new cancer therapies. Here, we review the current status of alpha v beta 3-integrin in tumour angiogenesis. Learning from what we now know about integrin conformational changes and endocytosis, we discuss the possible future of targeting blood vessel avb3-integrin in the control of cancer.

引用

页码：121 / 127

页数：7

共 54 条

[21]

Gutheil JC, 2000, CLIN CANCER RES, V6, P3056

[22] Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization [J].